BAMOMAB

Anti-Human **MICA/B Monoclonal Antibody** BAMO1

Antigen: **Human MICA and MICB**

Clone: BAMO1, mouse IgG1

Catalog Number: BAMO1-250

Specificity: binds: MICA*01, MICA*04, MICA*07, MICA*08
MICB*02

Epitope: in $\alpha1\alpha2$ superdomain of MICA/B
linear epitope independent of glycosylation



Human B cell line C1R transfected with vector (light grey), MICA*01 (black), or MICB*02 (dark grey), was stained with BAMO1 and anti-mouse Ig-PE conjugate.

Applications: Flow cytometry, ELISA, Immunoblot

Size: 250 µg, 1.0 mg/ml, in 0.25 ml phosphate-buffered saline, pH 7.4 with 0.05% sodium azide (**Caution**: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing).

Usage: For immunoblotting we recommend a final dilution of 1 µg BAMO1/ml.
In general, for flow cytometry we recommend a final dilution of 10µg mAb/ml and for ELISA 1-10 µg mAb/ml.

Purification: Protein A affinity chromatography

Storage: Store at 4°C. For long-term storage freezing at -80°C is recommended.

Description: MICA and MICB (MHC class I-related chain A) are polymorphic, human MHC-encoded cell surface glycoproteins and ligands of the activating C-type lectin-like immunoreceptor NKG2D [1-5]. NKG2D engagement of MICA/B activates NK cells and costimulates CD8 T cells [3,6]. MICA is expressed on gastrointestinal epithelium and inducible by cell stress, viral and bacterial infection [2,6-8]. MICA and MICB are also expressed by malignant epithelial and haematopoietic cells, and MICA expression has been shown to enhance tumor rejection in vivo [9-12]. Tumor cells shed soluble MICA and MICB which are detectable in sera of patients with epithelial and haematopoietic malignancies and may counteract tumor immunosurveillance [10,12-14].

Conditions: **For research use only. Not for use in diagnostic or therapeutic procedures. BAMOMAB is not responsible for any patent infringements caused by the use of this product.**

Country of Origin: Germany

Literature:

1. Bahram S et al. *Proc Natl Acad Sci USA* **91**, 6259-6263 (1994).
2. Groh V et al. *Proc Natl Acad Sci USA* **93**, 12445-12450 (1996).
3. Bauer S et al. *Science* **285**, 727-729 (1999).
4. Steinle A et al. *Immunogenetics* **53**, 279-287 (2001).
5. Li P et al. *Nat Immunol* **2**, 443-451 (2001).
6. Groh V et al. *Nat Immunol* **2**, 255-260 (2001).
7. Spies T *Proc Natl Acad Sci USA* **99**, 2584-2586 (2002).
8. Welte S et al. *Eur J Immunol* **33**, 194-203 (2003).
9. Groh V et al. *Proc Natl Acad Sci USA* **96**, 6879-6884 (1999).
10. Salih HR et al. *Blood* **102,** 1389-1396 (2003).
11. Friese MA et al. *Cancer Res* **63**, 8996-9006 (2003).
12. Wiemann K et al. *J Immunol* **175**, 720-729 (2005).
13. Salih HR et al. *J Immunol* **169**, 4098-4102 (2002).
14. Groh V et al. *Nature* **419**, 734-738 (2002).

BAMOMAB GmbH, Ruffiniallee 15a, 82166 Gräfelfing, Germany.
Fax ++49-(0)89-3303-7335 www.bamomab.com order@bamomab.com